Retrospective database study from Japan of PsA pts: At 12/24 mos ffg tx initiation, 37.5%/49% of pts discontinued index bDMARD while 22.2%/31.2% switched tx. Dc rates lowest for risankizumab 🤔Reasons for switching/discontinuation not mentioned. #ACR23 ABST2246 @RheumNow https://t.co/6dhKZmp1wE

A#2313 #ACR23 @RheumNow Utilization of inpt palliative care incr from 2016-2020 in SLE admits from 1.8% 2016 to 2.6% 2020 Pall care use incr: older pt, comorbid index, teaching, large hosps Lower use: age <35 yo, Black & Hispanic race Need to address racial disparities in utiliz https://t.co/wQ8NOhm9lK https://t.co/3tJgt4MMDf

Extended-Release Fluticasone Propionate for Injectable Suspension - EP-104IAR Phase 2 Randomized (1:1), Double-blind, Vehicle-Controlled Trial 318 pts, 57% F, age 64, Clinically and statistically significant pain relief for 14 weeks compared to vehicle @RheumNow #ACR23 #abstL04

Important data re:ADVOCATE study and health related quality of life Interesting question: is this due to AVA or just simply giving less steroids? I discuss this on recent podcast: https://t.co/7Jm6ArFpsB @RheumNow #ACR23 https://t.co/53T1p2Vvyb

@EricFMorand SPOCS Study: A#2263 @ACR23 826 pts - 71% high IFN gene sig Mean SLEDAI-2K lower with low IFNGS 6mo: pts reports 1+ flare 19% high IFNGS, 16% low. Both grps 6.7% LLDAS, but remission 4% low/1.7% high In 36 mo, <10% LLDAS, <10% remission @earlyARA @RheumNow https://t.co/z5v4TBVuDG

Post hoc analysis of Ph2 AURA-LV & Ph3 AURORA1 ⬆️VOC-treated pts achieved CRR at 1yr vs. control arm (41.0% vs. 21.9%; OR 2.48, p< 0.0001) and PRR at 1yr (OR 2.3, p< 0.0001) Similar safety profiles VOC: Additional tx option for LN pts w/ UPCR >/=2g/g #ACR23 ABST2326 @RheumNow https://t.co/9z1n3s7umU

Very cool meta analysis of IL17i RCTs in PsA No change in MACE in DMARD naieve pts initiating IL17i across RCTs A skosh underpowered but worthwhile question & useful data @RheumNow #ACR23 Abstr2254 https://t.co/ZN8QYgSA1A

A#2297 #ACR23 @RheumNow Baseline IFNα predicts complete response at 2 yrs in LN HIgh IFNα: incr risk of 2+ renal flare Increase of 1 unit of IFNα incr risk of 2+ flares by 35% & risk of decr GFR IFNα cutoff 0.6 for 2+ flare, 1.3 for progr to eGFR <15 AUC 0.6 (weak predictor) https://t.co/FKeDJVNyYj

In this older grp of pts w/ chronic LBP, significant overlaps of deg & inflamm features on spinal imaging of DC, DISH & axSpA pts were seen Also, +comorbids: HTN in DC; DM in DISH; smoking in axSpA THM? DC & DISH are also axSpA mimics #ACR23 ABST1862 @Rheumnow @rheumarhyme https://t.co/uNIwRchF1g

HCQ improves complements A#2327 #ACR23 @RheumNow Petri @jhrheumatology @andreafava Pts w/ low complement & low HCQ levels In pts who increased HCQ WB level >50 ng/mL, incr in mean C3 (p=0.02) v HCQ that did not incr More nml C4 levels (p=.003) and incr mean C4 (p=.004) on HCQ https://t.co/J7PIuaRTO8

HCQ Discontinuation A#2343 #ACR23 @RheumNow 42 pts d/c HCQ 19% flared in past yr before d/c D/c reasons: retina tox 57%, self-dc 17%, other eye issue 12% 26% flare in yr after d/c - strongest ass for flare: mean C3, dsDNA+ at index visit https://t.co/d4TqneS46u

Another day, another bimekizumab (IL17i) study Across 2 trials, improved PsA specific QOL ("PsAID") metrics Nice to see focus on PROs & I always love a good spidergram @RheumNow #ACR23 Absr2249 https://t.co/dsLXstPzt2

The patients’ voice matters! Watch my interview with @LAlupusLady regarding how she manages #Lupus and her perspective about the disease @rheumnow #ACR23 @uptoTate https://t.co/P9KPJQEkRv

All of us need to remind each other to take care of yourself! Some tips from Dr. Whitney Marvin - exercise, date night, talking to a friend - take breaks, mindfulness - eating away from computer (as I type this on my desk, next to my lunch) @RheumNow #ACR23 https://t.co/UmmDqXRECN

Will postpartum BME ⏩axSpA-like structural lesions? Study by Varkas et al show there was no significant dev't of axSpA-like lesions on MRI in postpartum women 5 yrs after delivery. Postpartum BME likely sec to transient mech stress-induced SI BME #ACR23 ABST1892 @RheumNow https://t.co/KJ3DngmkbI